Latest News
-
Tuesday - April 2, 2019
Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines
Seed investment of Leaps by Bayer paves an exclusive leadership position for next generation oncology business / Research study from Stanford University suggests that vaccination with iPSCs may cure and prevent the development of many types of cancer » more
-
Tuesday - April 2, 2019
Thought leaders emphasize cattle health and well-being for the sustainable development of the beef industry
More than 220 cattle professionals engage over key topics of parasite control, bovine respiratory disease, reproduction, digital innovation and well-being at the 2nd Bayer International Beef Symposium » more
-
Friday - March 29, 2019
CVBD World Forum discuss a changing world in vector-borne Diseases
The 14th CVBD™ (Companion Vector-Borne Diseases) World Forum welcomed parasitologists, veterinary clinicians and epidemiology experts from around the world to discuss changing parasite and vector distributions in a changing world. / Latest data about spread and prevalence of VBDs from endemic to non-endemic regions & need for vets to be equipped with this data » more
-
Wednesday - March 27, 2019
Bayer statement on jury’s decision in phase two of California glyphosate trial » more
-
Wednesday - March 27, 2019
Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) 110th Annual Meeting:
Bayer to showcase latest oncology research at AACR 2019 underscoring its commitment to advancing the future of cancer care
Data presentation from ongoing Phase I study with BAY 2731954 (formerly LOXO-195), an oral and selective investigational next-generation TRK inhibitor, in patients who have progressed on or were intolerant to prior TRK inhibitors / Bayer committed to expanding its precision oncology portfolio by bringing forward additional projects in this field / Total of 30 presentations on promising projects across key areas of investigation: Oncogenic Signaling, Targeted Alpha Therapies and Immuno-Oncology, underscoring Bayer’s commitment to advancing the future of cancer care » more
-
Tuesday - March 26, 2019
Bayer receives positive opinion from European Medicines Agency for Baycox® Iron injection for piglets
Bayer’s novel, patented toltrazuril plus gleptoferron injectable combination is a step closer to European authorization » more
-
Monday - March 25, 2019
Bayer reaches settlement to resolve Xarelto™ litigation » more
-
Thursday - March 21, 2019
Digital health:
Bayer is taking collaboration with health care start-ups to the next level
G4A Partnerships strengthens focus on co-creation and scaling by committed partnerships / Collaboration programs are being combined and longer-term oriented » more
-
Tuesday - March 19, 2019
Bayer statement on jury’s decision in phase one of California glyphosate trial » more
-
Monday - March 18, 2019
Bayer Animal Health launches Seresto™ collar in China
The flea and tick collar Seresto™ is one of the fastest growing brands in the Animal Health industry. / The brand is now available in China where there is an enormous increase in pet ownership and growth of urban populations. / Implementation of effective counterfeit protection CapSeal with app support is included in the launch. » more
-
Thursday - March 14, 2019
Not intended for U.S. and UK Media – Neglected Tropical Diseases
Phase III clinical trial with Bayer’s nifurtimox demonstrates safety and efficacy of new formulation to treat children with Chagas disease
Largest clinical treatment study to date in pediatric patients with Chagas disease / Easily dividable and dispersible nifurtimox tablet for improved weight-adjusted dosing of newborns, infants, and children » more
-
Friday - March 8, 2019
Not intended for U.S. and UK Media
Bayer submits European marketing authorization application for darolutamide
Third submission for darolutamide in two weeks underscores Bayer´s commitment to fill an unmet need for men with nmCRPC worldwide / Regulatory submission based on positive data from Phase III study ARAMIS » more
-
Thursday - March 7, 2019
2018 Aspirin Social Innovation Awards from Bayer Cares Foundation
Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition
Innovative concepts with sustainable and systematic change potential honored by Bayer Foundation / Awards for five international initiatives that can help improve many millions of lives / Around EUR 650,000 presented to 39 initiatives offering new solutions to improve living conditions since 2010 » more
-
Tuesday - March 5, 2019
Bayer presents global dairy cattle health experts at 2nd Dairy Summit
Thought leaders address five core pillars to advancing dairy cattle health: calf resilience, fertility, metabolic health, udder health and well-being » more
-
Tuesday - March 5, 2019
Not intended for U.S. and UK Media
Bayer submits darolutamide for marketing authorization in Japan
Regulatory submission based on positive data from Phase III ARAMIS study » more
-
Thursday - February 28, 2019
Conviso™ Smart: Successful licensing agreement between Bayer AG, KWS SAAT SE and MariboHilleshög » more
-
Thursday - February 28, 2019
Not intended for U.S. and UK Media
Bayer presents next generation CT injector, MEDRAD™ Centargo, at European Congress of Radiology 2019
New CT injection system provides range of innovative features which simplify workflow to help ease increasing workload of radiology departments / CE mark certification expected this summer » more
-
Thursday - February 28, 2019
Award from the Bayer Science & Education Foundation:
Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
Scientist at the Institute for Cardiovascular Prevention at the Ludwig-Maximilians-University in Munich is honored for his outstanding research in the area of immunity of atherosclerosis-brain interfaces » more
-
Wednesday - February 27, 2019
Financial News Conference
Full Year 2018 Results » more
-
Wednesday - February 27, 2019
Fiscal 2018:
Bayer increases sales and earnings – leader in agriculture after acquisition
Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits/ Net income at 1.695 billion euros, impacted by one-time effects / Core earnings per share at 5.94 euros, above expectations / Net financial debt at 35.679 billion euros, significantly better than expected / Bayer confirms 2019 Group outlook and 2022 targets » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Wednesday, October 30, 2019
Q3 2019 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV